Inducing angiogenesis is a hallmark of cancers that sustains tumor growth and metastasis. Neovascularization is a surprisingly early event during the multistage progression of cancer. Cinobufagin, an important bufadienolide originating from Chan Su, has been clinically used to treat cancer in China since the Tang dynasty. Here, we show that cinobufagin suppresses colorectal cancer (CRC) growth in vivo by downregulating angiogenesis. The hierarchized neovasculature is significantly decreased and the vascular network formation is disrupted in HUVEC by cinobufagin in a dosedependent way. Endothelial apoptosis is observed by inducing reactive oxygen species (ROS) accumulation and mitochondrial dysfunction which can be neutralized by N-acetyl-l-cysteine (NAC). Expression of hypoxia-inducible factor 1α (HIF-1α) is reduced and phosphorylation of mTOR at Ser2481 and Akt at Ser473 is downregulated in HUVEC. Endothelial apoptosis is triggered by cinobufagin by stimulation of Bax and cascade activation of caspase 9 and caspase 3. Increased endothelial apoptosis rate and alterations in the HIF-1α/mTOR pathway are recapitulated in tumor-bearing mice in vivo. Further, the anti-angiogenesis function of cinobufagin is consolidated based on its pro-apoptotic effects on an EOMA-derived hemangioendothelioma model. In conclusion, cinobufagin suppresses tumor neovascularization by disrupting the endothelial mTOR/HIF-1α pathway to trigger ROS-mediated vascular endothelial cell apoptosis. Cinobufagin is a promising natural anti-angiogenetic drug that has clinical translation potential and practical application value.
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| INTRODUC TI ON
Angiogenesis is a hallmark of cancer.
1 Vascular endothelial cells begin to resuscitate even if the diameter of tumors is only approximately 0.2-2.0 mm. 2 This early angiogenic switch emerges in premalignant or in in situ carcinomas. Neovasculature promotes solid tumor growth and metastasis. 3 Therefore, targeting angiogenesis is one of the most conventional approaches for controlling tumor progression.
In 2018, colorectal cancer (CRC) was the third main cause of estimated cancer death in the USA. 4 CRC is the fifth most common cancer in China and the incidence rate has shown an upward trend from 2000 to 2011. 5 Chemotherapy is the treatment of choice for postoperative CRC patients. However, the influences of chemotherapeutic agents on angiogenesis are still controversial. Chemotherapy drugs such as cisplatin, doxorubicin and vincristine increase vessel densities in neuroblastoma. 6 However, the absolute counts of circulating endothelial cells, a biomarker for angiogenesis, were not changed after a 4-week gemcitabine treatment in pancreatic carcinoma patients. 7 On the contrary, low-dose metronomic chemotherapy docetaxel treatment effectively inhibited the growth of gastric tumor by decreasing microvessel number. 8 For breast cancer patients with highly angiogenic tumor subtypes, angiogenesis phenotype enhances chemotherapeutic resistance. These patients cannot derive sufficient benefit even after receiving intensified adjuvant chemotherapy. 9 Therefore, seeking more effective anti-angiogenic agents would renew our enthusiasm for this therapeutic strategy. 
| MATERIAL S AND ME THODS

| Materials
Cinobufagin was purchased from Chenguang Biotechnology (Baoji, China 
| Immunohistochemistry and TUNEL
Expression of CD31 in tumors was assessed by IHC staining as described previously. 22 In brief, paraffin-embedded tumor sections were incubated with anti-CD31 antibody (1:100) overnight at 4°C, and then incubated with secondary antibody.
Apoptosis was evaluated by TUNEL assay (Roche diagnostics, Mannheim, Germany) following the manufacturer's instructions. The image of each case was captured using a fluorescence microscope (Nikon Eclipse-Ti; Nikon, Tokyo, Japan) and analyzed using ImagePro Plus 6.0 (IPP6) software.
| Chicken chorioallantoic membrane assay
Chicken chorioallantoic membrane (CAM) assay was carried out as described with modification. 23 Briefly, fertilized chicken eggs (South China Agricultural University) were incubated at 37°C for 10 days, and a window was then carefully created through the egg shell. 
| Tube formation assay
Tube formation assay was carried out as described by Nagata et al. 
| Migration assay
For HUVEC migration assay, Transwell inserts (8 μM pore; Corning Costar Corp., Cambridge, MA, USA) were used. HUVEC (5 × 10 4 cells/ well) were resuspended in a serum-free RPMI 1640 medium containing 0.1% BSA and seeded on the top chambers. RPMI 1640 (700 μL) with 10% FBS was added to the bottom chambers. HUVEC were coincubated with cinobufagin (0.1, 1, and 10 μM) and allowed to invade for 48 hours.
After 48 hours, the noninvasive cells on the upper surface of the filter were removed by a cotton swab. The invaded cells were stained with 0.1% crystal violet, and counted in five random fields per well. 
| Analysis of mitochondrial membrane potential
The experiment was conducted according to the protocols provided by the manufacturer (Beyotime Biotechnology). Then, both red fluorescence and green fluorescence were measured by flow cytometry.
| Reactive oxygen species analysis
Cinobufagin-treated HUVEC and control group cells were stained 
| Western blotting
Total protein was extracted with RIPA buffer (Beyotime Biotechnology) and quantified using a BCA protein assay kit (Beyotime Biotechnology) following the manufacturer's instructions and then western blot was carried out as described. 22 ECL solution was mixed for luminescent image development, and target protein levels were analyzed by Image J software with β-actin as a reference protein for loading control.
| Statistical analysis
All experimental data are shown as mean ± standard deviation.
Experiments were repeated three times. Statistical analysis was conducted by one-way ANOVA using statistical package SPSS 20.0 (Chicago, IL, USA). P < .05 was considered a statistically significant difference.
| RE SULTS
| Cinobufagin inhibits orthotopic CRC growth by suppressing angiogenesis in vivo
The antineoplastic effects of cinobufagin were tested on mice bearing orthotopically implanted colorectal carcinomas as described previously. 11, 22 The weight of tumor in situ was significantly reduced by cinobufagin and DDP ( Figure 1A ,C). Tumor size was also downregulated by cinobufagin in a dose-dependent way as evaluated by vernier caliper ( Figure 1D ). Body weight of mice was obviously lowered by DDP ( Figure 1B) . However, the rapid weight loss was ameliorated in mice treated with cinobufagin CD31 is a widely used angiogenic marker for the measurement of microvessel density (MVD). 25, 26 Expression of CD31 and vascular area were dose dependently decreased in tumor tissues by cinobufagin treatment ( Figure 1E,F) . Collectively, these results
showed that cinobufagin decreases CRC growth by downregulating angiogenesis.
| Cinobufagin suppresses endothelial cell migration and angiogenesis
Neovasculature forms a hierarchized and stereotypic network that is lined with endothelial cells in normal tissues, whereas an abnormal and chaotic network forms within the tumor. CAM assay was conducted as an in vivo approach to validate the putative anti-angiogenic effects of cinobufagin. The number of primary, secondary and tertiary blood vessels was dose-dependently reduced by a 4-day cinobufagin treatment in 8-day-old fertilized eggs ( Figure 2A ).
The ability of endothelial cells to engage in vascular morphogenesis was assessed by tubular formation test. 27 By using cultured HUVEC, we found that vascular networks were formed spontaneously in control conditions. The formation of these structures was significantly abolished upon cinobufagin treatment ( Figure 2B ).
The migration of endothelial cells is an early step for the sprouting and elongation of a newly formed vessel. 28 Cinobufagin significantly inhibited endothelial cell migration compared to control ( Figure 2C ).
Together, these assays recapitulate the endothelial functions during angiogenesis. Cinobufagin suppresses neovascularization by dampening endothelial migration and tubular formation.
| Cinobufagin induces endothelial cell apoptosis
The viability of HUVEC was significantly lowered by cinobufagin in a dose-and time-dependent way ( Figure S1 ). To clarify the potential anti-angiogenic mechanism of cinobufagin, cell apoptosis was first probed with Hoechst 33342 staining. The positive ratios of HUVEC ( Figure 3A) were essentially upregulated by cinobufagin. The results were further confirmed through double staining of Annexin V and 7-AAD by flow cytometry ( Figure 3B ).
Furthermore, ROS inhibitor NAC lowered the cell apoptosis ratio caused by cinobufagin ( Figure 3C ), suggesting that cinobufagin causes apoptosis and lowers cell viability through triggering oxidation reactions in HUVEC.
| Cinobufagin disrupts mitochondrial membrane potential and induces ROS accumulation
JC-1 is a fluorescent, lipophilic, cationic dye that can be used to effectively distinguish between apoptotic and healthy cells. Flow cytometry showed that mitochondrial membrane potential was exhausted dose-dependently by cinobufagin ( Figure 4A ).
ROS production was subsequently checked by DCFH-DA staining. ROS level was increased with dose escalation of cinobufagin ( Figure 4B ), indicating that cinobufagin-induced ROS accumulation and mitochondrial dysfunction are the driving force of apoptosis.
| Cinobufagin cleaves caspase-3 and downregulates mTOR signaling
Mitochondrial membrane potential depletion will lead to the initiation of mitochondrial outer membrane permeability (MOMP). mTOR is a key nutrient and energy sensor that regulates metabolic processes. mTOR hyperactivation is the driving force for angiogenesis. 31 Cinobufagin downregulated phosphorylation of mTOR at ser2481 in HUVEC, suggesting that deactivation of endothelial mTOR inhibits endothelial cell proliferation and migration.
Collectively, cinobufagin suppresses the survival pathway in HUVEC through downregulation of HIF-1α and dephosphorylation of Akt and mTOR.
| Cinobufagin activates endothelial apoptosis in vivo
To verify the pro-apoptotic effects of cinobufagin in vivo, tumor tissue slides were double stained with TUNEL and CD31 ( Figure 6A ). Cleavage of PARP, caspase-3 and -9 was increased by cinobufagin treatment. Bax expression was upregulated, representing the triggering of a mitochondrial apoptosis process ( Figure 6D ). Cinobufagin also reduced the expression of HIF-1α and significantly decreased the phosphorylation of mTOR and Akt, indicating that cinobufagin might be an mTOR inhibitor to suppress angiogenesis ( Figure 6E ).
Taken together, cinobufagin is an efficacious angiogenesis inhibitor through triggering endothelial apoptosis. It inhibits HIF-1α and dephosphorylates Akt and mTOR to switch the apoptosis program.
| Cinobufagin suppresses hemangioendo thelioma in vivo
The anti-angiogenic effects of cinobufagin in vivo were tested on mice bearing s.c. hemangioendothelioma EOMA. Tumor weight and tumor size were significantly reduced by cinobufagin, rapamycin and the endogenous angiogenesis inhibitor endostatin, respectively F I G U R E 5 Western blot analysis of the effect of cinobufagin on caspase and mTOR signaling. A, Effect of cinobufagin on the caspase pathway (Bax, Bcl-2, caspase-3, cleaved-caspase-3, caspase-9 and cleaved-caspase-9) in HUVEC cells. Western blot analysis was carried out to detect changes in the levels of Bax, Bcl-2, caspase-3, cleaved-caspase-3, caspase-9 and cleaved-caspase-9 after treatment with 0, 0.1, 1, 10 μM cinobufagin for 24 h (n = 3). B, Effect of cinobufagin on the expression of hypoxia-inducible factor 1α (HIF-1α), mTOR, p-mTOR (ser2481), Akt, and p-Akt (ser473) (n = 3). HUVEC cells were treated with various concentrations of cinobufagin (0, 0.1, 1, and 10 μM) for 24 h, and then the levels of proteins were detected by western blot analysis ( Figure 7A,C,D) . Surprisingly, body weight of mice was obviously lowered by mTOR inhibitor rapamycin ( Figure 7B ). To further verify the pro-apoptotic effects of cinobufagin in vivo, hemangioendothelioma tissue slides were double stained with TUNEL and CD31
( Figure 7E ). Similar to rapamycin and the endogenous angiogenesis inhibitor endostatin, cinobufagin upregulated apoptotic endothelial vascular cells but with a much stronger effect ( Figure 7F ).
Cinobufagin reduced the expression of HIF-1α and significantly decreased the phosphorylation of mTOR and Akt similar to rapamycin ( Figure 7G ), and similar to the result shown in Figure 6E . Collectively, we confirmed that cinobufagin suppresses angiogenesis by regulating mTOR signaling with lower toxicity compared with DDP. Our results suggest that cinobufagin inhibits the Akt-HIF-1α signaling axis. 38 Together, cinobufagin exerts its anti-angiogenesis effects by inhibiting these survival pathways of HUVEC.
| D ISCUSS I ON
Bcl-xL translation is regulated by mTOR through phosphorylation of its known target, 4E-BP1. resistance to cancer cells. 40 Evasion of apoptosis may represent an important hallmark of many human cancers. Cinobufagin reduces neovascularization by increasing the ROS level which leads to mitochondrial dysfunction in endothelial cells. The ROS accumulation induced by oxidation reaction facilitates the triggering of MOMP by cinobufagin. Then, it stimulates caspases, which is a biochemical characteristic of apoptosis. 41 Cinobufagin treatment increases cleavage of caspase-9 dose-dependently. Activated caspase-9 in turn cleaves and activates caspase-3 to execute intrinsic apoptosis in HUVEC.
Specific Akt/mTOR double pathway targeting agent, such as everolimus, is available and efficacious in metastatic CRC patients. 42 However, everolimus treatment may induce therapy resistance by triggering a negative feedback loop which leads to ERK activation and Mcl-1 stabilization in colon cancer cells. 
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